Method for Determining the Response Probability of a Malignant Disease to Treatment with a Pharmaceutical Inhibitor

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a novel molecular diagnostic method that uses DNA methylation analysis of specific genes to predict whether a patient with a malignant (cancerous) disease is likely to respond to treatment with certain targeted pharmaceutical inhibitors (drugs), such as kinase inhibitors or other targeted therapies. It also covers medical uses of these inhibitors in patients identified as likely responders through this test, and provides kits for performing the methylation analysis.

Use CasesContent extracted from patent full text and abstract with AI.

• Guiding personalized cancer treatment decisions by selecting patients likely to benefit from targeted therapies based on DNA methylation patterns.
• Screening patients with various types of malignant cancers to optimize therapy and avoid ineffective treatments.
• Developing companion diagnostic kits for clinical laboratories to predict therapy response in oncology.
• Supporting development of new clinical protocols based on predictive biomarkers for targeted inhibitors in cancer management.
• Enabling pharmaceutical companies and hospitals to reduce treatment costs and side effects by focusing therapies on patients most likely to benefit.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides an objective, reliable, and specific method to predict which cancer patients will benefit from targeted drug therapies, regardless of cancer type or specific genetic mutation.
• Reduces unnecessary exposure to ineffective drugs, thereby minimizing side effects and improving patient outcomes.
• Enables more personalized, efficient, and cost-effective cancer treatment by supporting precision medicine approaches.
• Applies broadly across many cancer types and a wide range of targeted inhibitor drugs (kinases, PARP, mTOR, etc.), unlike existing tests that are limited to certain mutations or cancers.
• Improves clinical decision-making, shortens the time to effective therapy, and decreases costly treatment failures.
• Can be implemented with standard molecular biology techniques and is compatible with existing laboratory workflows and sample types (including blood, tissue biopsies, FFPE samples, etc.).

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to molecular diagnostic methods in the field of oncology, which allow the response of persons with a malignant disease to treatment with specific pharmaceutical inhibitors to be predicted using a DNA methylation analysis of specific genes. The invention also relates to applications of pharmaceutical inhibitors in medical methods for treating malignant disease in persons of whom it is known, using the DNA methylation of specific genes, that they are likely to respond to treatment with said pharmaceutical inhibitors. Finally, the invention relates to kits for carrying out the specified methods and for the specified applications.